Aker Solution

C.A. Lassen, Layer of Protection Analysis (LOPA) for Determination of Safety Integrity Level (SIL) Stud. Techn., Aker Solutions NTNU, June 2008. 

Aker Solutions, 63000333-000-000-0005, Rev 2, Technical Specification for Decommissioning Strategy for the AP 1000 Generic Design Assessment, August 2008. 

Aker Solutions Kansai Nanko power plant in Osaka, Japan CO2 removal from flue gas Liqui-Cel membrane Herzog and Falk-Pedersen [86]... 

Aker Solutions Chevron Texaco gas plant in Texas Natural gas dehydration Liqui-Cel membrane — ... 

Aker Solutions TNO, GKSS in Hamburg, and at Gore in Munich Natural gas treatment PTFE membrane ... 

Aker Solutions Offshore and on shore installation Gas turbine exhaust treatment GORE-TEX ePTFE Under commercialization ... 

Aker Solutions—from Herzog and Pedersen Kvaerner W.L. Gore Co. Gas terminal pilot plant (Aberdeen, Scotland) State oil gas terminal, Norway Removal of exhaust gas GORE-TEX ePTFE membrane/aqueous MDEA GORE-TEX ePTFE Pressure regulation (problem for high pressure of natural gas). Exhaust gas flow rate 2610 kg/h, 85% (195 kg/h) of COj separated from exhaust gas Pressure 88 bar(g), gas flow rate 5000 Nm /h, liquid flow rate 5 m /h, CO2 content reduced 6% to 3.5% ... 

The direct-solution method of Akers and Wade [1] is among several which attempt to reduce the amount of trial-and-error solutions. This has been accomplished and has proven quite versatile in application. The adaptation outlined modifies the symbols and rearranges some terms for convenient use by the designer [3]. Dew point and bubble point compositions and the plate temperatures can be determined directly. Constant molal overflow is assumed, and relative volatility is held constant over sections of the column. 

Akers W, Haidekker MA (2004) A molecular rotor as viscosity sensor in aqueous colloid solutions. J Biomech Eng 126(3) 340-345... 

Akers MJ, Defelippis MR. Peptides and proteins as parenteral solutions. In Frokjaer S, Hovgaard L, eds. Pharmaceutical Formulation Development of Peptides and Proteins. (Pharmaceutical Science.) U.K. Taylor and Francis, 1999. 

Akers, L.C., Williams, M.C. Oscillatory normal stresses in dilute polymer solutions. J. Chem. Phys. 51,3834-3841 (1969). 

A Student s Solutions Manual by Hugh Akers, Lamar University, and Caroline Breitenberger, Ohio State University, provides detailed, worked-out solutions for the odd-numbered problems found in the text. This solutions manual can help students to better understand how to solve the problems in the text and prepare for exams. (ISBN 22870)... 

Michael J. Akers Baxter Pharmaceutical Solutions, Bloomington, Indiana, U.S.A. 

Jansen PJ, Akers MJ, Amos RM, Baertschi SW, Cooke GG, Dorman DE, Kemp CAJ, Maple SR, McCune KA. The degradation of the anti-tumor agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products. J Pharm Sci 2000 89(7) 885-891. 

Equation (5-2) considers the thermal conductivity to be variable. If k is expressed as a function of temperature, Eq. (5-2) is nonlinear and difficult to solve analytically except for certain special cases. Usually in complicated systems numerical solution by means of computer is possible. A complete review of heat conduction has been given by Davis and Akers [Chem. Eng., 67(4), 187, (5), 151 (I960)] and by Davis [Chem. Eng., 67(6), 213, (7), 135 (8), 137 (I960)]. 

Akers, M.J. DeFelippis, M.R. Peptides and proteins as parenteral solutions. In Pharmaceutical Formulation... 

For solution-based systems, a simple system based on dissolving the drug candidate in water or a pH 7.4 aqueous buffer should be attempted. Failing in this, pH adjustment is usually the easiest and safest manner to improve the solubility of an acidic or basic drug in aqueous media. For parenteral products, the range of pH values found in marketed products is reasonable wide (2-12) (Sweetana and Akers 1996 Strickley 2004). For biocompatibility reasons, it is recommended that the pH of the vehicle be maintained between 4 and 8, however values outside of this range may be considered. Similar limits for oral products should be considered although wider latitude may be justified. 

Akers MJ. Preformulation screening of antioxidant efficiency in parenteral solutions. J Parenteral Drug Assoc 1979 33 346-356. 

Prior to nomination into full development, a candidate drug should undergo a phase traditionally called preformulation. Preformulation is the physicochemical characterization of the solid and solution properties of compounds and although now relatively old, the definition of preformulation proposed by Akers (1976) is particularly apt ... 

Development of a solution formulation requires a number of key pieces of preformulation information. Of these, solubility (and any pH dependence) and stability are probably the most important. Since parenteral products probably represent the most common solution formulation type, these are discussed in more detail. The principles and practices governing the formulation development of parenteral products have been reviewed by Sweetana and Akers (1996) and are discussed in detail in Chapter 9 on Parenteral Dosage Forms. Rowe et al. (1995) have described an expert system for the development of parenteral products. 

Preformulation screening of the antioxidant efficiency in parenteral solutions containing epinephrine has been reported by Akers (1979), who concluded that screening was difficult on the basis of the redox potential, and was complicated by a complex formulation of many components. Indeed, the most recent study on the preformulation screening of antioxidants found that the ability of an antioxidant to consume the oxygen in the formulation was a superior indicator of suitability when compared to redox methods (Ugwu and Apte 1999). 

Almost every operation involving the manipulation of microbial suspensions, solutions or suspensions of material or of finely divided powders generates an aerosol. Operations which are known to generate an aerosol have been extensively reviewed by Chatigny, Darlow and Dimmick and Akers. 

N Milton, M Akers, S Nail. The crystallization kinetics of glycine hydrochloride from frozen solution. Cryo-Letters 18 335-342, 1997. 

Prins, A., Dynamic surface properties and foaming behaviour of aqueous surfactant solutions, in Foams (Akers, R.J., ed.). Academic Press, London, 1977, p45. 

---